SCIENCE THAT moves^TM

Science never stands still. We drive it forward, accelerating high-impact therapies in autoimmune diseases and cancer by uniting exceptional scientific expertise, strategic risk-taking, and rigorous decision-making to improve peoples’ lives.

At Cullinan Therapeutics, we believe in a future where people living with autoimmune diseases and cancer spend less time managing their conditions and more time on what matters most.

WHERE SPEED MEETS STRATEGY

Our clinical-stage pipeline reflects a deliberate approach of advancing only the most promising molecules to address high unmet needs and achieve the greatest potential impact for people living with autoimmune diseases and cancer.

Explore our pipeline

LATEST UPDATES

ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA INITIATED FOR ZIPALERTINIB

Regulatory review initiated for zipalertinib for patients with locally-advanced or metastatic NSCLC with EGFR ex20ins mutations who have previously received platinum-based systemic chemotherapy

NEW CLINICAL DATA FOR CLN-049 IN ACUTE MYELOID LEUKEMIA TO BE SHARED IN ORAL PRESENTATION AT ASH

Novel investigational T cell engager demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population, regardless of FLT3 mutational status

CORPORATE UPDATE AND THIRD QUARTER 2025 FINANCIAL RESULTS

Strategically focusing resources and development efforts on select, high-conviction clinical stage programs

INNOVATING WITH INTENT

The best science not only moves forward — it moves people. Our approach to therapeutic innovation centers around leveraging our deep expertise in immune modulation to deliberately develop and advance therapies that deliver meaningful outcomes for patients and their loved ones.

Discover our approach to autoimmune diseases and cancer

SCIENCE THAT movesTM